Study of hsCRP, adiponectin, NF-κB in low bodyweight, standard bodyweight and obese subjects with type 2 diabetes mellitus in India


Introduction: Low bodyweight type 2 DM is a distinct clinical entity having many inherent peculiarities seen in India and developing countries, constituting 11% to 25% of type 2 diabetic subjects. Our study aimed at assessing the prevalence of inflammatory markers like hsCRP, adiponectin and NF-κB expression in peripheral blood mononuclear cells in subjects with type 2 DM in relation to BMI. Materials and Methods: 57 consecutive type 2 diabetics were recruited for study, classified as Low Bodyweight (A = BMI < 18.5), Standard weight (B = BMI 18.5 - 24.99) and Obese (C = BMI ≥ 25). Group D comprised 14 healthy controls. They were evaluated for clinical parameters, FBG, 2hrPPBG, HbA1c, lipid profile and above mentioned inflammatory markers. Results: Serum hsCRP was significantly higher in all group of diabetics as compared to Group D but was lowest in Group A. Adiponectin levels were highest in Group D, similar in Groups B and C but lowest in Group A. NF-κB expression, though higher in diabetic subjects than controls (OD = 0.041 ± 0.006), was least in Group A (OD = 0.045 ± 0.005). Discussion and Conclusion: Our study revealed that Indians with type 2DM are in a pro-inflamematory state. Low bodyweight type 2 diabetics had the least pro-inflammatory load. This further supported the earlier observation of lesser macrovascular disease load and testifying that Low Bodyweight type2DM constitutes a distinct entity.

Share and Cite:

Das, S. , Prasanna Misra, D. and Kumari Sahu, P. (2012) Study of hsCRP, adiponectin, NF-κB in low bodyweight, standard bodyweight and obese subjects with type 2 diabetes mellitus in India. Journal of Diabetes Mellitus, 2, 386-392. doi: 10.4236/jdm.2012.24060.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Das, S. and Fonseca, V. (2009) Low bodyweight type 2 diabetes in India: Clinical characteristics and pathophysiology. Diabetes & Metabolic Syndrome: Clinical Research and Reviews, 3, 60-66. doi:10.1016/j.dsx.2009.01.001
[2] Diamond, J. (2011) Diabetes in India. Nature, 469, 478-479. doi:10.1038/469478a
[3] Tripathy, B.B. and Rao, H. (1996) Malnutrition and diabetes in the tropics. Report of the international workshop on types of diabetes peculiar to the tropics. Diabetes Care, 19, 1014-1017.
[4] Pickup, J.C. (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care, 27, 813-823. doi:10.2337/diacare.27.3.813
[5] Dandona, P., Aljada, A., Chaudhuri, A., Mohanty, P. and Garg, R. (2005) Metabolic syndrome: A comprehensive perspective based on interaction between obesity, diabetes and inflammation. Circulation, 111, 1448-1454. doi:10.1161/01.CIR.0000158483.13093.9D
[6] Ziemke, F. and Mantzoros, C.S. (2010) Adiponectin in insulin resistance: Lessons from translational research. The American Journal of Clinical Nutrition, 91, 258S-261S. doi:10.3945/ajcn.2009.28449C
[7] Kawano, J. and Arora, R. (2009) The role of adiponectin in obesity, diabetes and cardiovascular disease. Journal of the CardioMetabolic Syndrome, 4, 44-49. doi:10.1111/j.1559-4572.2008.00030.x
[8] Gustafson, B. (2010) Adipose tissue, inflammation and atherosclerosis. Journal of Atherosclerosis and Thrombosis, 17, 332-341. doi:10.5551/jat.3939
[9] Natarajan, R. and Nadler, J.L. (2004) Lipid inflammatory mediators in diabetic vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1542-1548. doi:10.1161/01.ATV.0000133606.69732.4c
[10] Das, S. (1994) Identity of lean-NIDDM: Clinical, metabolic and hormonal status. In: Kochupillai, N., Ed., Advances in Endocrinology Metabolism and Diabetes, Vol. 2, Macmillan, Delhi, 42-53.
[11] Das, S., Samal, K.C. and Baliarsinha, A.K. (1995) Lean (underweight) NIDDM-peculiarities and differences in metabolic and hormonal status. JR Assn Phys Ind, 43, 339-342.
[12] Das, S. (1999) low bodyweight type 2 diabetes mellitus, technical series. Indian College of Physicians (ICP), Academic Wing of Association of Physicians of India, Mumbai.
[13] Zimmet, P.Z., Tuomi, T., Mackay, I.R., Rowley, M.J., Knowles, W., Cohen, M. and Lang, A. (1994) Latent autoimmune diabetes mellitus in adults (LADA): The role of anti-bodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabetic Medicine, 11, 299-303. doi:10.1111/j.1464-5491.1994.tb00275.x
[14] Mohan, V., Vijayaprabha, R., Rema, M., Premlatha, G., Poongothai, S., Deepa, B.E., Mackay, I.R. and Zimmet, P. (1997) Clinical profile of lean NIDDM in South India. Diabetes Research and Clinical Practice, 38, 101-108. doi:10.1016/S0168-8227(97)00088-0
[15] Das, S., Bhoi, S.K., Baliarsinha, A.K. and Baig, M.A. (2007) Autoimmunity, insulin resistance and beta cell function in subjects with low body weight type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders, 5, 136-141.
[16] Das, S., Reynolds, T., Patnaik, A., Rais, N., Fink, L.M. and Fonseca, V.A. (1999) Plasma homocysteine concentrations in type 2 diabetics in India: Relationship to body-weight. Journal of Diabetes and Its Complications, 13, 200-203. doi:10.1016/S1056-8727(99)00045-8
[17] Lannergard, A., Friman, G., Ewald, U., Lind, L. and Larsson, A. (2005) Serum amyloid A (SAA) protein and high-sensitivity Creactive protein (hsCRP) in healthy newborn infants and healthy young through elderly adults. Acta Paediatrica, 94, 1198-1202. doi:10.1111/j.1651-2227.2005.tb02074.x
[18] Devaraj, S., Valleggi, S., Siegel, D. and Jialal, I. (2010) Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Current Atherosclerosis Reports, 12, 110-118. doi:10.1007/s11883-010-0098-3
[19] Pickup, J.C. and Crook, M.A. (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia, 41, 1241-1248. doi:10.1007/s001250051058
[20] Dhindsa, S., Tripathy, D., Mohanty, P., Ghanim, H., Syed, T., Aljada, A. and Dandona, P. (2004) Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear factor—kappaB in mononuclear cells. Metabolism, 53, 330-334. doi:10.1016/j.metabol.2003.10.013
[21] Hofmann, M.A., Schiekofer, S., Kanitz, M., Klevesath, M.S., Joswig, M., Lee, V., et al. (1998) Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care, 21, 1310-1316. doi:10.2337/diacare.21.8.1310
[22] Patnaik, A., Das, S. and Patnaik, B. (1999) Hepatic metabolic states and glucokinase. In: Das, S., Ed., Low Bodyweight Type 2 Diabetes Mellitus, Association of Physicians of India, Mumbai, 48-53.
[23] Das, S. and Sotaniemi, E.A. (1999) Hepatic microsomal enzymes and Cyto P450 activity. In: Das, S., Ed., Technical Series on “Low Bodyweight Type 2 Diabetes Mellitus”, Indian College of Physicians (Academic Wing of Association of Physicians of India), Mumbai, 54-58.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.